Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase

Nature Communications

Volumn 4, Issue , 2013, Pages

  Serrano, Isabel ^a   McDonald, Paul C ^a   Lock, Frances ^a   Muller, William J ^b   Dedhar, Shoukat ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; HIPPO TUMOR SUPPRESSOR PROTEIN; INTEGRIN LINKED KINASE; MERLIN; PROTEIN; PROTEIN KINASE YES; PROTEIN MYPT 1; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING MOTIF; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

CANCER; CELL ORGANELLE; DATA SET; ENZYME ACTIVITY; GROWTH; INHIBITION; TUMOR;

ARTICLE; BREAST TUMOR; CANCER INHIBITION; CARCINOGENESIS; COLON TUMOR; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN INACTIVATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MICE; MICE, TRANSGENIC; MYOSIN-LIGHT-CHAIN PHOSPHATASE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEUROFIBROMIN 2; NUCLEAR PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84890916735     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3976     Document Type: Article

References (55)

1. Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543-548 (2013).
2. Spencer, S L., Gaudet, S., Albeck, J G., Burke, J M. & Sorger, P K. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459, 428-432 (2009).
3. Bissell, M J. & Labarge, M A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7, 17-23 (2005). (Pubitemid 40126379)
4. Sanz-Moreno, V. et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 135, 510-523 (2008).
5. Zhao, B., Li, L., Lei, Q. & Guan, K L. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 24, 862-874 (2010).
6. Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 19, 491-505 (2010).
7. Nishio, M., Otsubo, K., Maehama, T., Mimori, K. & Suzuki, A. Capturing the mammalian Hippo: elucidating its role in cancer. Cancer Sci. 104, 1271-1277 (2013).
8. Hong, W. & Guan, K L. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin. Cell Dev. Biol. 23, 785-793 (2012).
9. Hao, Y., Chun, A., Cheung, K., Rashidi, B. & Yang, X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 283, 5496-5509 (2008).
10. Chen, D. et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med. 18, 1511-1517 (2012).
11. Kim, N G., Koh, E., Chen, X. & Gumbiner, B M. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc. Natl Acad. Sci. USA 108, 11930-11935 (2011).
12. Lamar, J M. et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc. Natl Acad. Sci. USA 109, E2441-E2450 (2012).
13. Yu, F X. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780-791 (2012).
14. Zhao, B. et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26, 54-68 (2012).
15. Halder, G., Dupont, S. & Piccolo, S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nature Reviews. Mol. Cell Biol. 13, 591-600 (2012).
16. Serrano, I., McDonald, P C., Lock, F E. & Dedhar, S. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFbeta-1-induced epithelial-mesenchymal transition (EMT). Oncogene 32, 50-60 (2013).
17. McDonald, P C., Fielding, A B. & Dedhar, S. Integrin-linked kinase-essential roles in physiology and cancer biology. J. Cell Sci. 121, 3121-3132 (2008).
18. Hannigan, G., Troussard, A A. & Dedhar, S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat. Rev. Cancer 5, 51-63 (2005). (Pubitemid 40052325)
19. Halder, G. & Johnson, R L. Hippo signaling: growth control and beyond. Development 138, 9-22 (2011).
20. Harvey, K F., Zhang, X. & Thomas, D M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246-257 (2013).
21. Troussard, A A. et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66, 393-403 (2006). (Pubitemid 43166047)
22. Muranyi, A L., Dedhar, S. & Hogge, D E. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk. Res. 34, 1358-1365 (2010).
23. Fan, R., Kim, N G. & Gumbiner, B M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositidedependent kinase-1. Proc. Natl Acad. Sci. USA 110, 2569-2574 (2013).
24. Varelas, X. et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev. Cell 19, 831-844 (2010).
25. Stanger, B Z. Quit your YAPing: a new target for cancer therapy. Genes Dev. 26, 1263-1267 (2012).
26. Stamenkovic, I. & Yu, Q. Merlin, a 'magic' linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr. Protein Pept. Sci. 11, 471-484 (2010).
27. Jin, H., Sperka, T., Herrlich, P. & Morrison, H. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 442, 576-579 (2006). (Pubitemid 44167917)
28. Li, W. et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140, 477-490 (2010).
29. Muranyi, A. et al. Phosphorylation of the myosin phosphatase target subunit by integrin-linked kinase. Biochem. J. 366, 211-216 (2002). (Pubitemid 34971820)
30. Kiss, E. et al. Integrin-linked kinase phosphorylates the myosin phosphatase target subunit at the inhibitory site in platelet cytoskeleton. Biochem. J. 365, 79-87 (2002). (Pubitemid 34756142)
31. Walsh, M P. et al. Rho-associated kinase plays a role in rabbit urethral smooth muscle contraction, but not via enhanced myosin light chain phosphorylation. Am. J. Physiol. Renal Physiol. 300, F73-F85 (2011).
32. Maydan, M. et al. Integrin-linked kinase is a functional Mn2\+-dependent protein kinase that regulates glycogen synthase kinase-3beta (GSK-3beta) phosphorylation. PLoS One 5, e12356 (2010).
33. Lau, Y K. et al. Merlin is a potent inhibitor of glioma growth. Cancer Res. 68, 5733-5742 (2008).
34. Cooper, J. et al. Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Sci. Signal. 4, pt6 (2011).
35. Pontier, S M. et al. Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene 29, 3374-3385 (2010).
36. Oloumi, A. et al. Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development. Breast Cancer Res. 12, R38 (2010).
37. Kalra, J. et al. Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267. Cancer Biol. Ther. 11, 826-838 (2011).
38. Eke, I., Leonhardt, F., Storch, K., Hehlgans, S. & Cordes, N. The small molecule inhibitor QLT0267 radiosensitizes squamous cell carcinoma cells of the head and neck. PLoS One 4, e6434 (2009).
39. Overholtzer, M. et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl Acad. Sci. USA 103, 12405-12410 (2006). (Pubitemid 44267272)
40. Poon, C L., Zhang, X., Lin, J I., Manning, S A. & Harvey, K F. Homeodomaininteracting protein kinase regulates Hippo pathway-dependent tissue growth. Curr. Biol. 22, 1587-1594 (2012).
41. Apte, U. et al. Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology 50, 844-851 (2009).
42. Yokoyama, T. et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 29, 2139-2146 (2008).
43. Baia, G S. et al. Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol. Cancer Res. 10, 904-913 (2012).
44. Yu, F X. & Guan, K L. The Hippo pathway: regulators and regulations. Genes Dev. 27, 355-371 (2013).
45. Hannigan, G E., McDonald, P C., Walsh, M P. & Dedhar, S. Integrin-linked kinase: not so 'pseudo' after all. Oncogene 30, 4375-4385 (2011).
46. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183 (2011).
47. Chan, S W. et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68, 2592-2598 (2008).
48. Steinhardt, A A. et al. Expression of Yes-associated protein in common solid tumors. Hum. Pathol. 39, 1582-1589 (2008).
49. Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761 (2007). (Pubitemid 350070721)
50. Zhao, B., Li, L., Tumaneng, K., Wang, C Y. & Guan, K L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev. 24, 72-85 (2010).
51. Imajo, M., Miyatake, K., Iimura, A., Miyamoto, A. & Nishida, E. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. EMBO J. 31, 1109-1122 (2012).
52. Rosenbluh, J. et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473 (2012).
53. Oloumi, A., Syam, S. & Dedhar, S. Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells. Oncogene 25, 7747-7757 (2006). (Pubitemid 44967969)
54. Fielding, A B., Lim, S., Montgomery, K., Dobreva, I. & Dedhar, S. A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells. Oncogene 30, 521-534 (2011).
55. Serrano, I. et al. Integrin-linked kinase (ILK) modulates wound healing through regulation of hepatocyte growth factor (HGF). Exp. Cell Res. 318, 2470-2481 (2012).